{"id":477340,"date":"2025-06-16T00:00:00","date_gmt":"2025-06-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrhe0001-2025-biopharma-hemophilia-a-current-treatment-current-treatment-physician-insights-hemophilia-a-us\/"},"modified":"2026-03-31T10:25:58","modified_gmt":"2026-03-31T10:25:58","slug":"cutrhe0001-2025-biopharma-hemophilia-a-current-treatment-current-treatment-physician-insights-hemophilia-a-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrhe0001-2025-biopharma-hemophilia-a-current-treatment-current-treatment-physician-insights-hemophilia-a-us\/","title":{"rendered":"Hemophilia A &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Hemophilia A (US)"},"content":{"rendered":"<p>Hemophilia A is a monogenic X-linked recessive bleeding disorder caused by the deficiency of clotting factor VIII. Prophylaxis, the typical care for hemophilia A patients, is especially preferred for patients with severe cases because it aims to reduce bleeding episodes and long-term joint complications. Hemlibra and factor VIII replacements are the standard of care for the management of inhibitor-naive patients, while therapies like Altuviiio and Hympavzi are important treatment alternatives that offer more-convenient dosing options. Roctavian, once considered a transformative therapy, faces adoption challenges due to variable long-term efficacy data affecting reimbursement and market access. Understanding the multifaceted decision points that hematologists encounter when treating inhibitor-naive hemophilia A patients is crucial for developers entering this market. This report provides a comprehensive analysis of the hemophilia A prophylaxis treatment landscape, with emphasis on inhibitor-naive patients.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which product attributes do U.S. hematologists perceive as most important for treatment of their hemophilia A patients?<\/li>\n<li>How do factors such as mode of drug administration, drug delivery, and formulary access influence choice of therapy?<\/li>\n<li>What patient shares do the <abbr title=\"factor VIII\">FVIII<\/abbr> replacement therapies garner among inhibitor-naive hemophilia A patients by severity? Which therapies are most preferred among the <abbr title=\"factor VIII\">FVIII<\/abbr> replacements?<\/li>\n<li>What will be the impact of novel agents such as Altuviiio and Hympavzi for the inhibitor-naive hemophilia A market? What will drive use of such therapies, and what will be their source of business?<\/li>\n<li>What are the recent and anticipated changes in hemophilia A treatment practices?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p>Geographies: United States.<\/p>\n<p>Primary research: Survey of 100 hematologists.<\/p>\n<p>Key drugs covered: Hemlibra, Altuviiio, Hympavzi, (<abbr title=\"standard half-life\">SHL<\/abbr> and <abbr title=\"extended half-life\">EHL<\/abbr>) recombinant factor VIII replacement therapies, Roctavian.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul>\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-477340","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hemophilia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/477340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/477340\/revisions"}],"predecessor-version":[{"id":477694,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/477340\/revisions\/477694"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=477340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}